Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.80 |
| ▸ | HTR2A | P28223 | 8/20 | 0.80 |
| ▸ | HTR1A | P08908 | 5/20 | 0.75 |
| ▸ | DRD2 | P14416 | 4/20 | 0.75 |
| ▸ | HTR7 | P34969 | 4/20 | 0.75 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15503471 | 1.00 | HTR6 (0.80) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL4807140 | 0.99 | HTR6 (0.78) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3560702 | 0.91 | HTR6 (0.73) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL14400458 | 0.90 | HTR6 (0.82) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3562663 | 0.90 | HTR6 (0.82) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3561641 | 0.90 | HTR6 (0.72) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5068818 | 0.89 | HTR6 (0.77) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3132360 | 0.89 | HTR6 (1.00) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3558256 | 0.88 | HTR6 (0.72) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3559568 | 0.87 | HTR6 (0.71) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | claimed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | claimed |
| CN-1315809-C | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2007-05-16 | — | — | CN | claimed |
| CN-1656075-A | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | CN | claimed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | claimed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| US-10660878-B2 | Methods of treating dementia and pharmaceutical compositions thereof | H. LUNDBECK A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-20180071254-A1 | METHODS OF TREATING DEMENTIA AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2018-03-15 | — | — | US | disclosed |
| US-9789085-B2 | Methods of treating dementia and pharmaceutical compositions thereof | H. LUNDBECK A/S (DK) | 2017-10-17 | — | — | US | disclosed |
| WO-2017147601-A1 | METHODS OF IMPROVING BALANCE, GAIT OR BOTH IN PATIENTS WITH NEUROLOGICAL DISEASE | AXOVANT SCIENCES GMBH (CH) | 2017-08-31 | — | — | WO | disclosed |
| US-9687473-B2 | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | H. LUNDBECK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| US-9642837-B2 | — | — | 2017-05-09 | — | — | US | disclosed |
| EP-1663980-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| CN-1656075-A | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | CN | disclosed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | disclosed |
| WO-2005026125-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR6 111/4885HTR2A 124/4885HTR1A 132/4885 |
| US-10660878-B2 | Methods of treating dementia and pharmaceutical compositions thereof | ACHE, BCHE, CHAT | HTR6 67/4885HTR2A 130/4885HTR1A 192/4885 |
| US-20180071254-A1 | METHODS OF TREATING DEMENTIA AND PHARMACEUTICAL COMPOSITIONS THEREOF | ACHE, BCHE, CHAT | HTR6 67/4885HTR2A 130/4885HTR1A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.